Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 62.5%Moderate 0 · 0%High 2 · 25%

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

All‐cause mortalityh

CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.52]
2 studies · 22610 participants
Low

Systemic reactogenicity events

CoronaVac – Sinovac showed no clear difference in systemic reactogenicity eventsj compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.19 [1, 1.42]
6 studies · 23966 participants
Low

Any adverse evento

CoronaVac – Sinovac leads to higher any adverse evento compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.09 [1.07, 1.11]
6 studies · 23367 participants
High

Serious adverse eventsr

CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.97 [0.62, 1.51]
4 studies · 23139 participants
Low

Local reactogenicity events

CoronaVac – Sinovac leads to higher local reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.76 [1.69, 1.82]
6 studies · 23962 participants
High